NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIDA E-053-2016-1-SI-29 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders SI EP 17711971.6 Issued
NIDA E-053-2016-1-SK-30 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders SK EP 17711971.6 Issued
NIDA E-053-2016-1-ES-13 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders ES EP 17711971.6 Issued
NIDA E-053-2016-1-NO-23 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders NO EP 17711971.6 Issued
NIDA E-053-2016-1-AT-07 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders AT EP 17711971.6 Issued
NIDA E-053-2016-1-BE-08 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders BE EP 17711971.6 Issued
NIDA E-053-2016-1-NL-22 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders NL EP 17711971.6 Issued
NIDA E-053-2016-1-IT-21 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders IT EP 17711971.6 Issued
NIDA E-053-2016-1-IE-20 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders IE EP 17711971.6 Issued
NIDA E-053-2016-1-GR-17 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders GR EP 17711971.6 Issued
NIDA E-053-2016-1-HU-19 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders HU EP 17711971.6 Issued
NIDA E-053-2016-1-DK-12 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders DK EP 17711971.6 Issued
NIDA E-053-2016-1-CZ-10 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders CZ EP 17711971.6 Issued
NIDA E-053-2016-1-HR-18 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders HR EP 17711971.6 Issued
NIDA E-053-2016-1-DE-11 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders DE EP 17711971.6 Issued
NIDA E-053-2016-1-FR-15 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders FR EP 17711971.6 Issued
NIDA E-053-2016-1-FI-14 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders FI EP 17711971.6 Issued
NIAID E-118-2016-0-BR-04 Live Attenuated Zika Virus Vaccine BR National Stage 1120180683426 Abandoned
NIAID E-118-2016-0-US-14 LIVE ATTENUATED ZIKA VIRUS VACCINE US National Stage 16/083,652 Abandoned
NIAID E-102-2016-0-US-04 RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE US National Stage 16/083,359 10808011 Issued PDF
NIDCD E-043-2016-0-US-07 MICRORNAS AND METHODS OF THEIR USE US National Stage 16/082,852 11655469 Issued PDF
NCI E-257-2009-1-US-24 Use Of IL-15 To Increase Thymic Output US DIV 16/123,431 1104-10-08 Issued PDF
NHGRI E-149-2017-0-PCT-02 BIOMARKERS OF ORGANIC ACIDEMIAS PCT PCT PCT/US2018/049757 Expired
NHGRI E-149-2017-0-EP-03 BIOMARKERS OF ORGANIC ACIDEMIAS EP National Stage 18788915.9 Abandoned
NIAID E-106-2016-0-EP-03 PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE EP National Stage 17712275.1 Pending
NCI E-241-2016-0-EP-05 Micro-Dose Calibrator EP National Stage 18779123.1 Issued
NCI E-241-2016-0-CH-01 Micro-Dose Calibrator CH EP 18779123.1 Issued
NCI E-241-2016-0-GB-01 Micro-Dose Calibrator GB EP 18779123.1 Issued
NCI E-241-2016-0-FR-01 Micro-Dose Calibrator FR EP 18779123.1 Issued
NCI E-241-2016-0-DE-01 Micro-Dose Calibrator DE EP 18779123.1 Issued
NCI E-241-2016-0-ES-01 Micro-Dose Calibrator ES EP 18779123.1
NCI E-241-2016-0-IT-01 Micro-Dose Calibrator IT EP 18779123.1
NCI E-229-2018-0-US-03 AZA-A-RING INDENOISOQUINOLINE TOPOISOMERASE I POISONS US National Stage 16/081,959 10759795 Issued PDF
NCI E-241-2016-0-PCT-02 Micro-Dose Calibrator PCT PCT PCT/US2018/049399 Expired
NCI E-241-2016-0-AU-03 Micro-Dose Calibrator AU National Stage 2018329661 Pending
NCI E-241-2016-0-CA-04 Micro-Dose Calibrator CA National Stage 3073559 Pending
NCI E-105-2012-0-HK-12 Murine Anti-NY-ESO-1 T Cell Receptors HK National Stage 18111203.0 Issued
NCI E-105-2012-0-US-14 MURINE ANTI-NY-ESO-1 T CELL RECEPTORS US DIV 16/115,969 10407485 Issued PDF
NCATS E-232-2017-0-JP-07 Deuterated Alpha5 Subunit-selective Negative Allosteric Modulators Of Gamma-Aminobutyric Acid Type A Receptors As Fast Acting Treatments For Depression And Mood Disorders JP National Stage 2020-512001 Issued
NCATS E-232-2017-0-EA-09 Novel Gamma Aminobutynic Acid Type A Receptor Modulators for Mood Disorders EA National Stage 202090521 Issued
NCATS E-232-2017-0-US-03 Deuterated Alpha5 Subunit-selective Negative Allosteric Modulators Of Gamma-Aminobutyric Acid Type A Receptors As Fast Acting Treatments For Depression And Mood Disorders US National Stage 16/642,445 11459320 Issued PDF
NCATS E-232-2017-0-PCT-02 Deuterated Alpha5 Subunit-selective Negative Allosteric Modulators Of Gamma-Aminobutyric Acid Type A Receptors As Fast Acting Treatments For Depression And Mood Disorders PCT PCT PCT/US2018/048339 Expired
NCATS E-232-2017-0-CN-13 Novel Gamma Aminobutynic Acid Type A Receptor Modulators for Mood Disorders CN National Stage 2018800656534 Pending
NCATS E-232-2017-0-EP-04 Novel Gamma Aminobutynic Acid Type A Receptor Modulators for Mood Disorders EP National Stage 18852438.3 Pending
NCATS E-232-2017-0-KR-11 Novel Gamma Aminobutynic Acid Type A Receptor Modulators for Mood Disorders KR National Stage 10-2020-7008731 Pending
NCATS E-232-2017-0-CA-06 Deuterated Alpha5 Subunit-selective Negative Allosteric Modulators Of Gamma-Aminobutyric Acid Type A Receptors As Fast Acting Treatments For Depression And Mood Disorders CA National Stage 3074110 Pending
NCATS E-232-2017-0-IN-12 Deuterated Alpha5 Subunit-selective Negative Allosteric Modulators Of Gamma-Aminobutyric Acid Type A Receptors As Fast Acting Treatments For Depression And Mood Disorders IN National Stage 202027012300 Pending
NCATS E-232-2017-0-MX-08 Deuterated Alpha5 Subunit-selective Negative Allosteric Modulators Of Gamma-Aminobutyric Acid Type A Receptors As Fast Acting Treatments For Depression And Mood Disorders MX National Stage MX/a/2020/002196 Pending
NCATS E-232-2017-0-BR-05 Deuterated Alpha5 Subunit-selective Negative Allosteric Modulators Of Gamma-Aminobutyric Acid Type A Receptors As Fast Acting Treatments For Depression And Mood Disorders BR National Stage BR112020004116-5 Pending
NCATS E-232-2017-0-AU-10 Novel Gamma Aminobutynic Acid Type A Receptor Modulators for Mood Disorders AU National Stage 2018323443 Pending